Dent Neurologic


Signal- AD Trial

The purpose of the study is to investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in people with early AD dementia (early AD). The primary hypothesis being tested is whether pepinemab will be safe and provide benefits in clinical assessments of cognition and in brain metabolism as measured by FDG-PET.

What is Alzheimer’s Disease?

Alzheimer’s is a progressive brain disease that leads to dementia and affects memory, thinking and behavior. Symptoms eventually become severe enough to interfere with daily tasks. Alzheimer’s is not just a normal part of aging, although the majority of people with Alzheimer’s are 65 and older. Risk factors such as aging, genetics, and lifestyle, can lead to destructive processes to the cells in the brain, including neurons and the cells that support the neurons, called glial cells. This damage can induce inflammation and interfere with the ability of glial cells to perform normal functions, such as supplying energy to the brain.

There is currently no cure for Alzheimer’s Disease. Therapies that treat the underlying disease process and reduce inflammation hold promise to slow the worsening of dementia symptoms and improve quality of life for those with Alzheimer’s and their caregivers.

Inclusion Criteria:

  • The age of 55 – 85 years old
  • Alzheimer Disease
    (MMSE range 17-26)

What to Expect:

  • All patients who enroll in the trial will receive treatment once each month by intravenous infusion.

For more information, tap the link above or go to 

Subscribe To Our Newsletter

Sign up to receive email updates on announcements, new services added, company updates & more!

Want to participate in a study?

Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.

Scroll to Top